HDM1002

2 papers4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs

Human trial2

Outcomes

Body weight

downin humans2

2 studies

HDM1002 decreases body weight in humans (-4.63% to -6.83% vs -2.88%).
“In obese adults without diabetes, HDM1002 showed statistically significant reductions in BW at wk 12 compared with PBO”
Human trialoverweight or obesity without diabetes12 weeksn = 185
Efficacy and Safety of a Novel Oral Small Molecule GLP-1 Receptor Agonist HDM1002 in Chinese Overweight and Obese Adults: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
ADA Scientific Sessions 2026 abstract5 Jun 2026
HDM1002 decreases body weight in humans (-4.3 kg to -6.1 kg (-4.9% to -6.8%) for doses ≥200 mg per day).
“Dose-dependent body weight reduction was observed on Day 29, ranging from -4.3 kg to -6.1kg in mean body weight change and -4.9% to -6.8% in percentage change for doses ≥200mg per day.”
Human trial4 weeks
HDM1002 in Chinese Adults with Overweight or Obesity—A Randomized, Placebo-Controlled, Four-Week, Phase 1b Study
ADA Scientific Sessions 2025 abstract13 Jun 2025

Glycated hemoglobin

downin humans1

1 study

HDM1002 decreases glycated hemoglobin in humans.
“HDM1002 also showed reductions in waist circumference, BMI, SBP, ALT and HbA1c compared with in PBO from BL at week 12.”
Human trialoverweight or obesity without diabetes12 weeksn = 185
Efficacy and Safety of a Novel Oral Small Molecule GLP-1 Receptor Agonist HDM1002 in Chinese Overweight and Obese Adults: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
ADA Scientific Sessions 2026 abstract5 Jun 2026